Guggenheim Capital LLC Neurocrine Biosciences Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 32,032 shares of NBIX stock, worth $4.02 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

32,032

Previous 50,147 36.12%

Holding current value

$4.02 Million

Previous $6.9 Million 46.59%

% of portfolio

0.03%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $2.08 Million - $2.77 Million	-18,115 Reduced 36.12%	32,032 $3.69 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.65 Million - $1.81 Million	12,629 Added 33.66%	50,147 $6.9 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $1.12 Million - $1.23 Million	8,579 Added 29.65%	37,518 $5.17 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.08 Million - $1.35 Million	-10,169 Reduced 26.0%	28,939 $3.81 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $487,775 - $607,514	-5,188 Reduced 11.71%	39,108 $4.4 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $216,214 - $253,261	2,415 Added 5.77%	44,296 $4.18 Million
Q1 2023 May 10, 2023	SELL	$94.11 - $123.02 $24,939 - $32,600	-265 Reduced 0.63%	41,881 $4.24 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $144,178 - $171,658	-1,351 Reduced 3.11%	42,146 $5.03 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $348,057 - $407,737	-3,782 Reduced 8.0%	43,497 $4.62 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $758,127 - $1 Million	-10,003 Reduced 17.46%	47,279 $4.61 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $355,005 - $464,569	-4,900 Reduced 7.88%	57,282 $5.37 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $274,712 - $366,352	3,449 Added 5.87%	62,182 $5.3 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $113,929 - $130,917	-1,322 Reduced 2.2%	58,733 $5.63 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $814,349 - $931,270	9,106 Added 17.87%	60,055 $5.85 Million
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $1.06 Million - $1.44 Million	12,056 Added 31.0%	50,949 $4.96 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $30,592 - $38,132	352 Added 0.91%	38,893 $3.73 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $575,132 - $808,332	-5,981 Reduced 13.43%	38,541 $3.71 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $356,101 - $545,556	4,185 Added 10.38%	44,522 $5.43 Million
Q1 2020 Jun 02, 2020	SELL	$75.11 - $113.76 $665,474 - $1.01 Million	-8,860 Reduced 18.01%	40,337 $3.49 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $685,372 - $936,228	7,896 Added 19.12%	49,197 $5.29 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $735,604 - $890,764	-8,776 Reduced 17.53%	41,301 $3.72 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $499,178 - $630,675	-6,910 Reduced 12.13%	50,077 $4.23 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $28,001 - $36,978	404 Added 0.71%	56,987 $5.02 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $354,580 - $645,428	5,190 Added 10.1%	56,583 $4.04 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $428,150 - $544,930	-4,330 Reduced 7.77%	51,393 $6.32 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $195,177 - $274,726	-2,592 Reduced 4.44%	55,723 $5.47 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $572,135 - $696,922	-7,540 Reduced 11.45%	58,315 $4.84 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $1.55 Million - $2.06 Million	-26,490 Reduced 28.69%	65,855 $5.11 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $4.43 Million - $5.66 Million	92,345	92,345 $5.66 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Neurocrine Biosciences Inc Transaction History